Menu
Not yet recruiting NCT07698613

EGFR Targeted Photoimmunotherapy With ASP-1929 for Locally Advanced Pancreatic Cancer

Phase I / Phase II Interventional Pancreatic Cancer Patients Diagnosed With Locally Advanced or Metastatic Pancreatic Cancer Not Amenable to Curative Surgical Resection Pancreatic Cancer Borderline Pancreatic Cancer Resectable

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: ASP-1929 photoimmunotherapy.
Who it may be relevant to
Registry conditions: Pancreatic Cancer Patients Diagnosed With Locally Advanced or Metastatic Pancreatic Cancer Not Amenable to Curative Surgical Resection, Pancreatic Cancer Borderline, Pancreatic Cancer Resectable. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

BrUOG 438: EGFR Targeted Photoimmunotherapy With ASP-1929 for Locally Advanced Pancreatic Cancer

Overview

This is an open label phase II study to determine the safety and preliminary efficacy of photoimmunotherapy (PIT) for patients with locally advanced and borderline resectable pancreatic cancer.

Interventions

  • Combination product ASP-1929 photoimmunotherapy
    Approximately 24 hours prior to surgery, patients will receive ASP-1929, IV over 2 hours, in the outpatient clinic. ASP-1929 is an EGFR targeting antibody conjugated with a laser-light activable dye IR700 (IRDye 700DX). The following day patients will undergo standard surgical exploration. Those patients found to be inoperable on surgical exploration will be treated with the laser device (Alluminox platform) over 5 minutes in the operating room to activate ASP-1929 photoimmunotherapy. Activation

Primary outcome measures

  • Incidence of treatment related toxicities grade ≥3 [Time frame: From start of treatment to 28 days post surgery]
  • Number of Participants Reaching 6 Months Progression Free Survival [Time frame: From start of treatment to 6 months post surgery.]

Eligibility criteria

Inclusion criteria

  • Pathologically confirmed pancreatic adenocarcinoma.
  • Clinically staged locally advanced or borderline resectable pancreatic adenocarcinoma.
  • Completed neoadjuvant chemotherapy
  • Neoadjuvant radiation is allowed
  • Planned surgical exploration
  • Treatment with ASP-1929 will be at least 4 - 10 weeks after last chemotherapy and radiation.
  • Patients with a history of biliary obstruction must have adequate biliary drainage.
  • Patients meeting the following laboratory criteria for Adequate Organ and Bone Marrow Function:

Platelet Count ≥ 75,000/mm3. Hemoglobin ≥ 8.0 g/dL \[NOTE: Participants requiring ongoing transfusions or growth factor support to maintain hemoglobin ≥8.0 g/dL are not eligible\] Absolute neutrophil count ≥ 1,000/mm3. \[Granulocyte-colony stimulating factor administration is not allowed within 1 week prior to C1D1\] Alanine aminotransferase (ALT) ≤ 3×ULN Aspartate aminotransferase (AST) ≤ 3×ULN Total Bilirubin ≤ 1.5×ULN or < 3×ULN in the presence of documented Gilbert's syndrome (unconjugated hyperbilirubinemia) Creatinine ≤ 3×ULN

  • Age ≥ 18
  • ECOG performance status 0-1
  • For women of pregnancy potential, a negative pregnancy test within 7 days prior to registration.
  • Ability to understand and the willingness to sign a written informed consent document.

Exclusion criteria

  • Patients with distant metastases.
  • Patients with medical co-morbidities that make them not candidates for surgical exploration
  • Planned concomitant, non-protocol directed anti-cancer therapy for at least 8 weeks after ASP-1929
  • Patients with unresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet resolved to Grade ≤ 1 or baseline. Note: Subjects may be enrolled with chronic, stable Grade 2.
  • History of significant (Grade ≥ 3) cetuximab infusion reactions
  • Photosensitizing medications must be discontinued 4 weeks before ASP-1929 PIT treatment, unless medically required.
  • No uncontrolled intercurrent illness including but not limited to symptomatic CHF, unstable angina, clinically significant severe cardiac arrhythmia, psychiatric illness or social situations that would limit compliance with study requirements.
  • Any other condition which, in the investigator's opinion, deems the patient an unsuitable candidate to receive ASP-1929 and/or be exposed to PIT illumination.
  • Women who are pregnant or nursing.
  • Patients with concomitant malignancies not expected to cause death within 5 years are eligible.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Treatment

Study locations

United States · 1 center
  • Rhode Island and the Miriam Hospitals (Brown University Health) — Providence

Identifiers

NCT: NCT07698613 · BrUOG 438 · 1929-IIR-0016

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗